TruFin plc (TRU) — Investment Research Note
Executive summary
TruFin is a Jersey-incorporated, AIM-listed holding company that, following the June 2026 disposal of its mobile-games publisher Playstack for £125m enterprise value, now owns two remaining operating businesses: Oxygen Finance (~85%, dominant UK local-government early-payment provider) and Satago (80%, invoice-finance / lending-as-a-service). Group revenue and profit trajectory 2023–2025 was strongly upward, driven almost entirely by Playstack, but with that engine now sold the continuing group is expected to be loss-making in 2026, targeting profitability in 2027 2026-05 disposal circular. The single most important valuation point today is that TRU has become a post-disposal cash shell (£35m unrestricted cash after the £70m tender and £6.2m LTIP payout) wrapped around Oxygen + Satago, with a stated strategy to acquire and scale further "platform" businesses.
Fair value estimate
Methodology: sum-of-the-parts / NAV, given the holding-company structure and recent asset sale.
Post-completion (June 2026 disposal, August 2026 special dividend and tender) building blocks:
| Component | Value (£m) | Basis |
|---|---|---|
| Unrestricted cash post capital return | 35 | Board's own guidance 2026-05 disposal circular |
| Oxygen stake (85%): 2025 EBITDA £3.8m growing high-teens, 100% retention, 7.7yr tenure | 32 (bear 25 / bull 45) | 10–14x EBITDA on 85% share |
| Satago stake (80%): 2025 rev £1.2m, loss-making, LaaS pilot phase | 4 (bear 2 / bull 10) | Optionality only |
| PV of central costs (Company LBT £3.7m in 2025, run-rate ~£3m) | (12) | 4x annual central drag |
| LTIP cash awards on capital return | (6) | Per circular |
| Equity value | 53 (bear 44 / bull 72) |
Divided across 53.9m shares in issue: fair-value range ≈ 80p – 135p per share, mid ~100p, implied market cap £43m – £73m.
Vs. latest disclosed market cap of £52.5m at 92p, the mid-point is ~9% upside, but the range brackets today's price. Absolute upside to mid-point: +9%; to bull ~+47%; to bear ~–13%.
Sector context
Confirms ICB classification: Financial Services (holding company / diversified). But given the operating exposure – Oxygen is best characterised as public-sector procurement/finance SaaS and Satago as fintech LaaS – the true peer set sits closer to UK small-cap fintech/SaaS. Growth profile (Oxygen mid-teens organic) is above typical AIM financials peers; balance sheet is significantly cleaner (net cash) than typical peers; scale is well below. Closest listed reference points: Alpha FMC (financial-services technology/consulting), Beeks Financial Cloud (specialist fintech infra), and Time Finance / Distribution Finance Capital (SME lenders) — all imperfect analogues.
Investment thesis (three bullets)
- Cash-rich, disciplined capital allocator. Post-tender ~£35m unrestricted cash represents ~67% of current market cap; Board has a documented track record of returning capital (three share buybacks at avg 106p in 2025, £70m tender at 140p in 2026) 2026-03 final results; 2026-05 disposal circular.
- Oxygen is the crown jewel. 100% EP renewal rate, 7.7-year avg client tenure, 65 EP clients with 98%+ of 2026 EP revenue already contracted from existing clients; 2025 EBITDA grew 67% on 18% revenue growth, illustrating operating leverage; paid £2.5m dividend to Group in 2025 2026-03 final results.
- Optionality on new platform acquisitions. Stated criteria (EBITDA margin >40%, IRR >20%, resilient to AI disruption, fragmented markets) suggest disciplined bolt-on strategy; one platform identified, one Oxygen bolt-on in DD 2026-05 disposal circular. Any accretive deployment of cash at management's stated thresholds is upside optionality not in mid case.
Key risks (three bullets)
- Continuing group is loss-making in 2026 with no near-term catalyst. Playstack contributed £13.5m of 2025 group EBITDA of £12.6m — i.e. Oxygen + Satago net of central costs = broadly break-even at best. Company itself is expected to remain loss-making full-year 2026 2026-05 disposal circular.
- Capital-deployment execution risk. Board has 12 months to deploy proceeds into one new platform + Oxygen bolt-ons; overpayment or poor selection would destroy the SOTP margin of safety. No target has yet passed DD 2026-05 disposal circular.
- Concentration on Oxygen post-disposal. Oxygen is one dominant business with heavy UK public-sector exposure — the 2025 Procurement Act already caused H2 growth to slow to 12%; further fiscal/regulatory shifts would meaningfully hit group value 2025-09 half-year report; 2026-03 final results.
Operating leverage
Oxygen is the operating-leverage story: 2025 revenue grew 18% (£7.7m → £9.1m) while EBITDA grew 67% (£2.3m → £3.8m) and EBIT grew 383% — evidence of strong contribution margin on a largely fixed cost base of platform, salespeople and data infrastructure 2026-03 final results. Gross margin at Group level was 46% in 2025, and staff costs (£13.3m) are the dominant fixed cost. If the continuing group (Oxygen + Satago + central) had grown Oxygen revenue by an additional 20% (~£1.8m) at the observed ~70% incremental EBITDA margin, EBITDA would rise by roughly £1.2m — meaningful vs. the group's current ~zero base but not transformational in absolute terms given scale. Satago in isolation has extreme operating leverage if a Tier-1 LaaS partner is won (fixed platform, thousands of subs at low marginal cost), but this is embedded-option value, not a base-case earnings driver.
Value-trap signals
- Continuing group is loss-making and now much smaller / less liquid; risk that market re-rates it as a sub-scale shell rather than a growth platform.
- Playstack disposal removed the earnings engine that made 2024–2025 look exceptional; growth commentary in current-price momentum could mask that the story is essentially "buy the cash + Oxygen".
- Watrium (25.6%) elected not to tender and could end up at up to 54.6%, requiring Rule 9 waiver — concentrated shareholder dominance could dampen future strategic optionality.
- Central corporate loss (~£3–4m/yr) is a structural drag on any SOTP unless promptly deployed.
Earnings vs. expectations
Across the disclosed cycle TruFin has been a consistent beat-and-raise story: (i) Nov 2024 trading update guided Group PBT loss ≤£(2.5)m vs. earlier market view; (ii) Dec 2024 upgraded to positive PBT and further beat delivered £0.9m adj PBT for FY24; (iii) May 2025, Aug 2025, Dec 2025, Jan 2026 trading updates each raised full-year guidance — FY25 landed at £8.4m adj PBT vs. initial market ~£3m. This pattern has recurred at every interim update over the 2024–2026 window and reflects genuine outperformance rather than lowballing (multiple management commentary references "significantly ahead of expectations"). Post Playstack disposal the guidance base resets and the beat trajectory does not carry into the continuing group.
Conviction
3 — moderate. The SOTP methodology is unambiguous for a company that just sold its biggest asset for a hard cash number, and the fair-value range brackets today's price. Anchors: (a) confirmed £35m unrestricted post-return cash number from the shareholder circular; (b) Oxygen's audited 2025 EBITDA of £3.8m and clearly stated recurring-revenue model give a defendable multiple. Caveats: (a) Oxygen multiple is a judgement (10x–14x EBITDA) and materially swings the answer; (b) treatment of central-cost drag / new-platform execution is speculative; the range 80p–135p is wide.